N/A N=40 Randomized Quadruple-blind Treatment

Escitalopram Treatment of Night Eating Syndrome

Night Eating Syndrome

Bottom Line

View on ClinicalTrials.gov: NCT00636649 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

May 2013

Primary outcome: Primary: Night Eating Questionnaire — -13.0; -10.6 units on a scale

Study Design & Population

Study type: Interventional
Phase: N/A
Interventions: Escitalopram (Drug); Placebo (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: Duke University
Primary completion: Aug 2010

Outcome Measures

Outcome	Result	p-value
PRIMARY Night Eating Questionnaire	-13.0; -10.6	—
SECONDARY Change in Beck Depression Inventory II (BDI-II) Score	-2.4; -3.5	—
SECONDARY Change in Coping Inventory for Stressful Situations (CISS)	2.35; 1.75; 1.25; -1.45; 0; 2.60	0.993
SECONDARY Change in Perceived Stress Scale (PSS)	-0.55; -2.11	0.579
SECONDARY Change in Three Factor Eating Questionnaire (TFEQ)	2.95; 1.85; -0.85; -1.50; -1.60; -1.75	0.225
SECONDARY Number of Participants With a Clinical Global Impression - Improvement (CGI-I) Score ≤ 2	12; 7	—
SECONDARY Change in Lipid Panel	-2.8; -2.2; -3.9; 2.8; 27.5; -14.0	—
SECONDARY Change in Beck Anxiety Inventory (BAI) Score	-1.5; -1.8	—
SECONDARY Change in Glucose	3.9; 7.6	—
SECONDARY Change in Weight	-0.43; 1.12	—
SECONDARY Number of Participants Who no Longer Meet the NESHI Criteria	16; 12	—
SECONDARY Number of Participants Who Had a 50% Reduction in NEQ Scores	7; 6	—

Summary

Night-Eating Syndrome (NES) is an eating disorder characterised by excessive eating at night, sleep disturbance and morning anorexia. This 12-week study examines the effect of escitalopram on symptoms of NES.

Eligibility Criteria

Inclusion Criteria

Age 18-70 years
Presence of NES
BMI 25-50

Exclusion Criteria

History of schizophrenia or other psychoses
History of bipolar disorder, anorexia nervosa, bulimia, binge eating disorder
Current major depressive disorder
Suicidal ideation
Psychotropic drugs in the past month
Drugs or herbal remedies that significantly affect body weight, current participation in a weight loss program, currently following a specialized diet (e.g., Atkins, Zone, etc)
Lack of benefit with SSRI treatment for NES
Serious or unstable medical illness
Allergy or hypersensitivity to escitalopram
Pregnant, breast-feeding, or planning pregnancy in the next six months.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT00636649). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.